Melanoma Trial, Recruiting NCT07564570 Sponsor: Universitätsklinikum Hamburg-Eppendorf Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT07564570
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with metastatic malignant melanoma (melanoma that has spread to other parts of the body) that has been confirmed through laboratory testing of tissue samples, and for whom a type of immunotherapy treatment (the drugs Nivolumab and Ipilimumab) has been recommended.
  • People who are willing and able to provide written consent to participate in the study.
  • People who are at least 18 years old at the time of signing the consent form.
  • People who have not previously received any systemic drug treatments (such as chemotherapy or targeted therapy) for their metastatic disease.
  • People whose general health and ability to carry out daily activities meets a certain standard, rated on a scale used by medical professionals (confirm with trial site).
  • People who have no physical limitations that would prevent them from taking part in physical exercise as part of the study.

Who may not be able to join:

  • People who have had major surgery within the 2 weeks before the study begins, or who have not fully recovered from a previous surgery.
  • People who have a diagnosed condition that weakens the immune system, or who have been taking steroid medications at higher than a specified dose, or who have been on any other immune-suppressing medications in the 7 days before the first treatment dose.
  • People who currently have an active infection that requires treatment with systemic (whole-body) medications.
  • People with a known history of HIV or hepatitis infection.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 040 7410 0

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Registry
ClinicalTrials.gov
Start date
14 November 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Feasibility rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov